Triple negative breast cancer is the most aggressive type of breast cancer and most difficult to treat because it is not dependent on hormones or targeted Her2 proteins for growth that we can target with meds. These tumors will often become resistant to chemotherapy within a few treatments.
A new drug called Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a monoclonal antibody against a growth protein (Trop 2) found on breast cancer cells with a chemotherapy drug together to better facilitate cancer death. In this early trial setting (called a phase 1/2 trial), there were very promising results in triple negative breast cancer patients that had stopped responding to multiple other chemotherapies. The response rate was above 30% in this small study which was very encouraging compared to other chemos we may use. This drug needs to be compared in a randomized trial to other chemotherapy regimens before it can be approved by the FDA.